Clinuvel Pharmaceuticals Ltd (CUV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clinuvel Pharmaceuticals Ltd (CUV) has a cash flow conversion efficiency ratio of 0.050x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$12.52 Million ≈ $8.86 Million USD) by net assets (AU$249.02 Million ≈ $176.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Clinuvel Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Clinuvel Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Clinuvel Pharmaceuticals Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Clinuvel Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clinuvel Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VRG SA
WAR:VRG
|
0.016x |
|
CHEERWIN GRP. -0000002
F:1RQ
|
N/A |
|
Borussia Dortmund GmbH & Co KGaA
XETRA:BVB
|
-0.040x |
|
NOCIL Limited
NSE:NOCIL
|
0.077x |
|
Fujian Yongan Forestry Group Joint-Stock
SHE:000663
|
-0.019x |
|
Stalprodukt SA
WAR:STP
|
0.028x |
|
Aofu Environmental Technology Co Ltd
SHG:688021
|
0.023x |
|
Yungshin Construction & Development Co Ltd
TWO:5508
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Clinuvel Pharmaceuticals Ltd (2001–2025)
The table below shows the annual cash flow conversion efficiency of Clinuvel Pharmaceuticals Ltd from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see Clinuvel Pharmaceuticals Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$240.81 Million ≈ $170.39 Million |
AU$41.10 Million ≈ $29.08 Million |
0.171x | -6.50% |
| 2024-06-30 | AU$203.01 Million ≈ $143.64 Million |
AU$37.05 Million ≈ $26.22 Million |
0.183x | -18.59% |
| 2023-06-30 | AU$164.63 Million ≈ $116.49 Million |
AU$36.91 Million ≈ $26.12 Million |
0.224x | -29.40% |
| 2022-06-30 | AU$125.56 Million ≈ $88.84 Million |
AU$39.87 Million ≈ $28.21 Million |
0.318x | +62.78% |
| 2021-06-30 | AU$98.74 Million ≈ $69.86 Million |
AU$19.26 Million ≈ $13.63 Million |
0.195x | -0.91% |
| 2020-06-30 | AU$72.07 Million ≈ $50.99 Million |
AU$14.19 Million ≈ $10.04 Million |
0.197x | -39.00% |
| 2019-06-30 | AU$57.18 Million ≈ $40.46 Million |
AU$18.46 Million ≈ $13.06 Million |
0.323x | +8.80% |
| 2018-06-30 | AU$39.42 Million ≈ $27.89 Million |
AU$11.69 Million ≈ $8.27 Million |
0.297x | -23.88% |
| 2017-06-30 | AU$25.44 Million ≈ $18.00 Million |
AU$9.92 Million ≈ $7.02 Million |
0.390x | +238.00% |
| 2016-06-30 | AU$17.83 Million ≈ $12.62 Million |
AU$-5.04 Million ≈ $-3.56 Million |
-0.282x | +30.14% |
| 2015-06-30 | AU$11.21 Million ≈ $7.93 Million |
AU$-4.53 Million ≈ $-3.21 Million |
-0.404x | -29.70% |
| 2014-06-30 | AU$15.43 Million ≈ $10.92 Million |
AU$-4.81 Million ≈ $-3.40 Million |
-0.312x | +37.41% |
| 2013-06-30 | AU$13.84 Million ≈ $9.79 Million |
AU$-6.89 Million ≈ $-4.88 Million |
-0.498x | +32.24% |
| 2012-06-30 | AU$13.64 Million ≈ $9.65 Million |
AU$-10.02 Million ≈ $-7.09 Million |
-0.735x | -27.11% |
| 2011-06-30 | AU$16.41 Million ≈ $11.61 Million |
AU$-9.49 Million ≈ $-6.71 Million |
-0.578x | -29.67% |
| 2010-06-30 | AU$26.43 Million ≈ $18.70 Million |
AU$-11.78 Million ≈ $-8.34 Million |
-0.446x | -50.38% |
| 2009-06-30 | AU$37.05 Million ≈ $26.22 Million |
AU$-10.99 Million ≈ $-7.77 Million |
-0.296x | -113.93% |
| 2008-06-30 | AU$51.81 Million ≈ $36.66 Million |
AU$-7.18 Million ≈ $-5.08 Million |
-0.139x | -10.81% |
| 2007-06-30 | AU$65.39 Million ≈ $46.27 Million |
AU$-8.18 Million ≈ $-5.79 Million |
-0.125x | +84.66% |
| 2006-06-30 | AU$13.99 Million ≈ $9.90 Million |
AU$-11.40 Million ≈ $-8.07 Million |
-0.815x | +34.28% |
| 2005-06-30 | AU$7.45 Million ≈ $5.27 Million |
AU$-9.25 Million ≈ $-6.54 Million |
-1.240x | -82.98% |
| 2004-06-30 | AU$8.85 Million ≈ $6.27 Million |
AU$-6.00 Million ≈ $-4.25 Million |
-0.678x | -180.66% |
| 2002-06-30 | AU$10.31 Million ≈ $7.29 Million |
AU$-2.49 Million ≈ $-1.76 Million |
-0.242x | -531.42% |
| 2001-06-30 | AU$13.45 Million ≈ $9.52 Million |
AU$-514.54K ≈ $-364.07K |
-0.038x | -- |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more